Literature DB >> 18597127

Group A streptococcal infection caused by emm1 strains among children in southern Taiwan.

H-C Lin1, S-M Wang, Y-L Lin, Y-S Lin, J-J Wu, W-J Chuang, M T Lin, C-C Liu.   

Abstract

The aim of this study was to characterize the molecular epidemiology of invasive and non-invasive group A streptococcus (GAS) infections in children from 1997 through 2004 in southern Taiwan. A collection of 32 invasive and 150 non-invasive isolates were recruited for analysis. emm1 (34.4%) and emm12 (40.0%) predominated in the invasive and non-invasive isolates, respectively. The peak incidence of invasive GAS infection (IGASI) occurred between 2002 and 2003. emm4 and emm12 were the major types among clinical isolates before 2001, and was replaced by emm1 during 2002-2003. All emm1 isolates were clonal relatedness. The declined prevalence of erythromycin resistance occurred in the major shift of the endemic isolates to emm1 strains during 2002-2003 in the community.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18597127     DOI： 10.1007/s10096-008-0561-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  8 in total

1.  Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s.

Authors:  P P Cleary; E L Kaplan; J P Handley; A Wlazlo; M H Kim; A R Hauser; P M Schlievert
Journal:  Lancet       Date:  1992-02-29       Impact factor: 79.321

2.  Clonal differences within M-types of the group A Streptococcus revealed by pulsed field gel electrophoresis.

Authors:  L A Single; D R Martin
Journal:  FEMS Microbiol Lett       Date:  1992-02-01       Impact factor: 2.742

3.  Decreased erythromycin use after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan.

Authors:  Po-Ren Hsueh; Jainn-Ming Shyr; Jiunn-Jong Wu
Journal:  Clin Infect Dis       Date:  2005-03-15       Impact factor: 9.079

4.  Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms.

Authors:  D L Kiska; B Thiede; J Caracciolo; M Jordan; D Johnson; E L Kaplan; R P Gruninger; J A Lohr; P H Gilligan; F W Denny
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

5.  Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989.

Authors:  S E Holm; A Norrby; A M Bergholm; M Norgren
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

6.  Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections.

Authors:  Susan Rogers; Robert Commons; Margaret H Danchin; Gowri Selvaraj; Loraine Kelpie; Nigel Curtis; Roy Robins-Browne; Jonathan R Carapetis
Journal:  J Infect Dis       Date:  2007-04-26       Impact factor: 5.226

7.  Molecular characterisation of invasive Streptococcus pyogenes isolates from Hungary obtained in 2004 and 2005.

Authors:  B Krucsó; M Gacs; B Libisch; Zs Vargáné Hunyadi; K Molnár; M Füzi; J Pászti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

8.  Site-specific manifestations of invasive group a streptococcal disease: type distribution and corresponding patterns of virulence determinants.

Authors:  Bart J M Vlaminckx; Ellen M Mascini; Joop Schellekens; Leo M Schouls; Armand Paauw; Ad C Fluit; Rodger Novak; Jan Verhoef; Franz Josef Schmitz
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948
  8 in total
  1 in total

1.  Clustered Regularly Interspaced Short Palindromic Repeats Are emm Type-Specific in Highly Prevalent Group A Streptococci.

Authors:  Po-Xing Zheng; Yuen-Chi Chan; Chien-Shun Chiou; Chuan Chiang-Ni; Shu-Ying Wang; Pei-Jane Tsai; Woei-Jer Chuang; Yee-Shin Lin; Ching-Chuan Liu; Jiunn-Jong Wu
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.